

CURRICULUM VITAE

BERARDINO DE BARI, MD

04/09/25

Personal details:

Name: De Bari Berardino
Date of birth: 07/08/1979 in Roma (Italy)

Professional Address:

Réseau Hospitalier Neuchâtelois
Radiation Oncology Dpt.
Chasseral 20
2300 La Chaux-de-Fonds
Switzerland



Private Address : Route des Addoz 10a, 2017 Boudry (Switzerland)

Professional Phone Number: 0041 (0) 32 96 72 146
Personal Mobile Phone: 0041 (0) 79 55 35 191
Professional Email: Berardino.debari@rhne.ch
Private Email: Berardinodebari79@gmail.com

Education and qualification

2001 - 2003: Internship in General Pathology laboratory at Catholic University of Sacred Heart (UCSC, Rome)

2003 - 2004: Internship in the radiation oncology department of UCSC (Prof. N. Cellini / Prof. V. Valentini).

28.10.2004: Medical Degree *cum lauda* at UCSC. Research degree entitled: "Intraoperative radiotherapy, technical aspects and therapeutic indications".

2004 – 2008: Resident in radiotherapy at UCSC (Prof. N. Cellini / Prof. V. Valentini).

During the residency: in charge of a Quality Assurance program contributing to the renewal of accreditation by the American College of Radiation Oncology (ACRO).

27.10.2008: Specialization in Radiation Oncology *cum lauda* at UCSC. Research degree entitled: "Role of replanning for the optimization of IMRT treatment plans in Head and Neck cancers".

2008 – 2011: Chef de Clinique, Assistant des Hopitaux in Radiation Oncology at "Lyon Sud" University Hospital (France, Prof. F. Mornex / Prof. O. Chapet).

2011 - 2013: Fellowship in the Radiotherapy Department "Istituto del Radio – O. Alberti" of the Academic Hospital "Spedali Civili" in Brescia (Italy, Prof S. Magrini).

2013 – 2016: Radiation Oncologist in the Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne (Switzerland, Prof J. Bourhis).

Since 2016-2022: Private Docent and Lecturer (MERClin Type 1) of the University of Lausanne (UniL).

2016 - 2018: Radiation Oncologist of the radiation oncology department of the Centre Hospitalier Regional Universitaire "Jean Minjoz", Besançon (France, Dr. P. Bontemps).

2016 - 2017: Diploma in Medical Pedagogy (University of Lyon 1)

2018 - 2020: Lecturer - Radiation Oncologist of the radiation oncology department of the Centre Hospitalier Regional Universitaire "Jean Minjoz", Besançon (France, Dr. P. Bontemps).

2023: Advanced course on "History of Medicine and Bioethics" (University of Catanzaro, Italy)

Since 01.01.2020: Head of the Radiation Oncology Department of the Réseau Hospitalier Neuchâtelois (Switzerland)

08.07.2025: Inter-University Diploma (DIU) of History of Medicine (University of Lille – University of

Bourgogne Franche- Comté, France) (Final mark : 16/20)

Since 02.2025: Student of the Bachelor in Contemporary History (Unidistance, Switzerland)

Spoken languages :

Italian : Fluent, mother tongue

French: Fluent

English: Fluent

Scientific and Educational Activity History of Medicine

Memberships in Scientific Societies:

- Since 2024: Italian Society of History of Medicine
- Since 2024: French Society of History of Medicine

Distinctions :

- Member of the Accademia di Storia dell'Arte Sanitaria (Italian Academy of Sanitary Art)
-

Academic and non-academic teaching activities:

- Since 2023: Courses in History of Medicine for the Popular University of Neuchâtel (Switzerland)

Publications in History of Medicine

1. De Bari B. "Novembre 1911: "l'Affaire Langevin-Curie": quale fu la ricezione da parte della stampa svizzera?Atti e Memorie della Accademia di Storia dell'Arte Sanitaria. 2025, in press.

Scientific and Educational Activity in Radiation Oncology

Memberships in Scientific Societies:

- Italian Association of Radiation Oncology (A.I.R.O.) 2005 - 2019.
- Board member of Young A.I.R.O. 2008-2012 and Scientific coordinator 2012- 2014.
- European Society of Radiation Oncology (E.S.T.R.O.) since 2005.
- French Society of Radiation Oncology (Young S.F.R.O) since 2008 – 2012; 2016 - .
- Swiss Radiation Oncology (SASRO) since 2013-2016, 2021 - .

Other memberships :

- 2009-2011: Editorial Board of “Cancer Radiothérapie”.
- 2012-2014: board of the “Prostate cancer working group” of AIRO.
- 2015: board of the “Groupe Francophone de Radiothérapie Urologique (GFRU)”
- 2017 - : EORTC member
- 2017: Member of the Groupe d’étude des tumeurs urogénitales (GETUG)
- 2018-2019: Member of the scientific committee of the European Multidisciplinary Congress on Urological Cancers
- 2020 - : Member of the scientific Council of the European School of Oncology (ESCO)
- 2020 - : Member of the scientific Council and Teacher of the European School of Oncology (ESO)

Distinctions :

- Nominated in 2010 as an ESTRO Fellow
- 2011-2012: Member of the 1st ESTRO Young Task Force.
- 2012 - 2018 : Member of the board of the ESTRO FALCON core, and coordinator of the *online* and *onsite* workshops.
- 2017: Member of the Thesis Jury for the PhD lecture of Dr. Arturo Navarro, MD (Barcelona, Spain)

Reviewer for Scientific journals:

Cancer, Acta Dermato-venereologica, Radiation Oncology, Cancer Radiothérapie, Tumori, BMJ, British Journal of Radiology, Radiotherapy and Oncology, International Journal of Radiation Oncology Biology Physics, Frontiers in oncology, Frontiers in Oncology, BMJ Cancer, European Journal of Cancer....

Academic and non-academic teaching activities:

- 2010: for residential course at the Catholic University of Roma (Italy).
- 2004 - 2008: lessons for residents of the post-graduate school / UCSC.
- 2009 - 2010: DCEM2 and DCEM4 of “Lyon Sud” Faculty of Medicine.
Master in Physics in radiotherapy, University Lyon 1.
DES for residents in Radiation Oncology (Lyon 2, France).
- 2013 - 2016: for RTT students at the Superior Health School of Vaud
- 2013 - : member of the teachers of the ESTRO School (Contouring / Falcon Program/ ESTRO Course on Evidence Based Radiation Oncology/ ESTRO Course on Prostate Cancer).
- 2014 - : for students and residents of the University of Lausanne (Switzerland)
- 2016-2020 : for students and residents of the University of Bourgogne – Franche Comté (France)
- 2015- : member of the teaching staff of the International Agency of Atomic Energy (IAEA).
- 2020 - : teacher of the European School of Oncology (ESO)
- 2021 - : Mentor in the context of the ESTRO mentorship programme
- 2021 - : Mentor in the context of the ESO mentorship programme

- 2022 : Member of the teaching staff of the Master in Epidemiology of the University of Turin (coordinator Pr. F. Merletti)
- 2023: Member of the Council of Teachers of the PhD program in “Artificial Intelligence in medicine and Innovation in Clinical and Methodological Research” of the University of Brescia (Italy).
- 2023: Lecturer for the Popular University of Neuchatel (teaching courses of “History of Medicine”)

Coordination of Courses & Seminars:

- 2009 - 2011: scientific coordinator of Young AIRO session annual national congress
- 2009 - : chair and co-chair in the context of several ESTRO contouring workshops of the FALCON program (ESTRO meetings, IAEA courses, EMUC)
- 2011: member of Scientific Committee of Eurocancer (Paris)
- 2011-2012: Member of the Young ESTRO Task Force for shaping the future of ESTRO membership for young members
- 2016: Member of the GI scientific committee of in the context of the World Congress of Brachytherapy (San Francisco, USA).
- 2016: Member of the Oncologic cancer network
- 2017-2019: Responsible and teacher for the “Radiotherapy” session in the Academic Diploma “Cancerology” organized by the Medical Oncology Department of the CHRU “Jean Minjoz” of Besançon.
- 2020 - : Member of the Board of the European School of Oncology

Research Activity

Principal investigator of clinical projects / trials:

- Coordinator of the “INTER-ROMA Project” (INTERview for Radiation Oncologists on Metastasis Approach).
- Co-Coordinator of “PROCAINA Project” (PROstate CANcer INDications Attitudes).
- Co-Coordinator of “BUONGIORNO Project” (BUrn Out Nei GIOvani Oncologi Radioterapisti Negli Ospedali).
- Coordinator of the PEDRO project (Pocketable Electronic devices in Radiation Oncology: how clinical practice is changing among young radiation oncologists?)
- Responsible for research in gating for SBRT Radiotherapy Department in Lyon Sud.
- Responsible of protocol development for prostate cancer and upper GI cancers patients in the Radiotherapy Department of Spedali Civili di Brescia (Italy).
- Responsible for protocol development for prostate cancer, GI and lung cancer Radiotherapy at CHUV (Lausanne, Switzerland).
- Responsible for protocol development for prostate cancer, GI and lung cancer Radiotherapy at CHRU Jean Minjoz (Besançon, France).

Bibliometry (Google Scholar, period 2003 – 2024)

- **H-index:** 31 (Since 2020 : 23)
- **H10-index:** 88 (Since 2020 : 57)
- **Citations :** 3571 (Since 2020 : 2340)

Publications (with the * the articles as first second or last author with an IF ≥ 3)

Original articles

1. Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, Buatti JM, Giammarile F, Al-Ibraheem A, Pardo MA, Baum RP, De Bari B, Ben-Haim S, Blay JY, Brink A, Estrada-Lobato E, Fanti S, Golubic AT, Hatazawa J, Israel O, Kiess A, Knoll P, Louw L, Mariani G, Mirzaei S, Orellana P, Prior JO, Urbain JL, Vichare S, Vinjamuri S, Virgolini I, Scott AM. *Guiding principles on the education and practice of theranostics*. **Eur J Nucl Med Mol Imaging**. 2024 Jul;51(8):2320-2331. doi: 10.1007/s00259-024-06657-2. (IF: **8.6**).
2. Kaufmann E, Aeppli S, Arnold W, Balermipas P, Beyer J, Bieri U, Cathomas R, De Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann TRW, Hermanns T, Ilaria L, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Reinhardt K, Salati E, Sèbe P, Shelan M, Strebel R, Templeton AJ, Vogl U, Wettstein MS, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. *Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review*. **World J Urol**. 2024 Sep 19;42(1):527. doi: 10.1007/s00345-024-05196-7. (IF: **2.8**).
3. François E, Magné N, Boulahssass R, Ronchin P, Huguenet V, De Lavingerie B, Nouhaud E, Cattenoz C, Martel-Lafay I, Terret C, Artru P, Clavere P, Tchalla A, Vandrey V, Duc S, Boige V, De Sousa Carvalho N, Gal J, De Bari B. *Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42 / GERICO 12 study) : quality of life and comprehensive geriatric assessment*. **Radiother Oncol** 2024. Apr;193:110144. doi: 10.1016/j.radonc.2024.110144. DOI:https://doi.org/10.1016/j.radonc.2024.110144. (IF: **5.7**)*.
4. De Bari B, Guibert G, Slimani S, Yanes B, Risse T, Guisolan N, Troulliot J, Abel J, Patrick W. *Electromagnetic transmitter-based prostate gating for dose escalated Linac-Based Stereotactic Body Radiation Therapy: evaluation of the intrafraction motion*. **Curr. Oncol**. 2024, 31(2), 962-974; https://doi.org/10.3390/curroncol31020072. (IF: **2.6**).
5. Mathier E, Althaus A, Zwahlen D, Lustenberger J, Zamboglou C, De Bari B, Aebersold DM, Guckenberger M, Zilli T, Shelan M. *HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol*. **BMJ Open**. 2024 Jan 30;14(1):e075846. doi: 10.1136/bmjopen-2023-075846. (IF: **2.9**)*.
6. Deantonio L, De Bari B, Franco P. *Editorial: Ano-rectal and gastro-esophageal cancer: diving into diagnostic and therapeutic imaging modalities for radiotherapy*. **Front Oncol**. 2023 Aug 31;13:1276334. doi: 10.3389/fonc.2023.1276334. eCollection 2023. (IF: **4.7**)*.
7. Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jerezek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. *Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium*. **Lancet Oncol**. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. (IF: **54.43**).
8. Kim S, De Bari B, Spohner L. *Editorial: New understandings and research in anal squamous cell*

carcinoma. **Front Oncol.** 2023 Jan 16;12:1131678. doi: 10.3389/fonc.2022.1131678. eCollection 2022. (IF: 6.24)*.

9. François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, Magné N. *Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.* **Eur J Cancer.** 2023 Feb;180:62-70. doi: 10.1016/j.ejca.2022.11.020. Epub 2022 Nov 28. (IF: 10.0)*.
10. Nicosia L, Franceschini D, Perrone-Congedi F, Molinari A, Gerardi MA, Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci G, Chiesa S, Niespolo RM, Bruni A, Cappelli A, D'Angelo E, Borghetti P, Di Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C, Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I, Scarzello G, Vavassori V, Maranzano E, Maria Magrini S, Arcangeli S, Gambacorta MA, Valentini V, Paiar F, Ramella S, Di Muzio NG, Loi M, Jereczek-Fossa BA, Casamassima F, Osti MF, Scorsetti M, Alongi F. *A predictive model of polymetastatic disease from a multicenter large retrospective database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.* **Clin Transl Radiat Oncol.** 2022 Dec 20;39:100568. doi: 10.1016/j.ctro.2022.100568. eCollection 2023 Mar. (IF: 4.74).
11. De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, Vernerey D. *Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?* **Cancers (Basel).** 2022 Aug 22;14(16):4043. (IF: 6.63)*.
12. Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J. *Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.* **Front Oncol.** 2022 Jul 22;12:918271. (IF: 5.78).
13. Mauri D, Kamposioras K, Tsali L, Dambrosio M, De Bari B, Hindi N, Salembier C, Nixon J, Dimitrios T, Alongi F, Hameed H, Valachis A, Papadimitriou K, Corradini S, Popovic L, Kopecky J, Rodriguez A, Antunac K, Yi J, Lovey J, Strojanc P, Sarairoh H, Røtterud R, Chojnacka M, Olalla SC, Chilingirova N, De Mello RA, Amaral GA, Arbabi F, Vidra R, Rapushi E, Takeuchi D, Christopoulos C, Ivanova I, Djan I, Petricevic B, Cellini F, Mihaylova I, Plavetic ND, Kuhar CG, Takeuchi E, Kountourakis P, Ntellas P, Gazouli I, Gkoura S, Yuce S, Er Ö, Yasmina C, Kumaran G, Spahiu O, Yusuf A, Gono P, Apostolidis K, Tolia M. *COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.* **Rev Recent Clin Trials.** 2022;17(1):11-14. doi: 10.2174/1574887116666211028145848. (IF: 1.42).
14. Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci G, Chiesa S, Niespolo RM, Bruni A, Alicino G, Frassinelli L, Borghetti P, Di Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C, Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I, Scarzello G, Corti L, Vavassori V, Maranzano E, Magrini SM, Arcangeli S, Gambacorta MA, Valentini V, Paiar F, Ramella S, Di Muzio NG, Livi L, Jereczek-Fossa BA, Osti MF, Scorsetti M, Alongi F. *A multicenter Large retrospective daTabase on the personalization of stereotactic Ablative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study.* **Radiother Oncol.** 2022 Jan;166:92-99. (IF: 6.28).
15. Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedic N, Katsanos K, Mostert B, Alongi F, De Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A. *Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach.* **Oncol Res Treat.** 2022 Jan 9. doi: 10.1159/000521845. (IF: 2.82).
16. Valentini V, Cellini F, Riddell A, Brunner TB, Roeder F, Giuliantè F, Alfieri S, Manfredi R, Ardito F, Fiorillo C, Porziella V, Morganti AG, Haustermans K, Margaritora S, De Bari B, Matzinger O, Gkika E, Belka C, Allum W, Verheij M. *ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies.* **Radiother Oncol.** 2021 Sep 20;164:92-97. (IF: 6.28).
17. Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB,

- Franzese C, Hannoun-Levi JM, Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T, Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). *Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. **Cancer Treat Rev.*** 2021 Jul;98:102206. (IF: **12.11**).
18. De Bari B. *Cautious SBRT.* *Int J Radiat Oncol Biol Phys.* 2021 Feb 1;109(2):315. (IF: **7.03**)*.
 19. Roland A, Drouet C, Boulahdour H, Cochet A, De Bari B. *Unusual uptakes on 18F-fluorocholine positron emission tomography/computed tomography (PET/CT): a retrospective study of 368 prostate cancer patients referred for a biochemical recurrence or an initial staging. **Quant Imaging Med Surg.*** 2021 Jan;11(1):172-182. (IF: **3.83**)*.
 20. Rimini M, Franco P, De Bari B, Zampino MG, Vagge S, Frassinetti GL, Arcadipane F, Bacigalupo A, Valgiusti M, Aloï D, Gervaso L, Corvò R, Bartolini G, Gerardi MA, Cascinu S, Casadei-Gardini A. *The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation. **Cancers (Basel).*** 2021 Feb 7;13(4):671. (IF: **6.63**)*.
 21. Gatta R, Vallati M, Fernandez-Llatas C, Martinez-Millana A, Orini S, Sacchi L, Lenkovicz J, Marcos M, Munoz-Gama J, Cuendet MA, De Bari B, Marco-Ruiz L, Stefanini A, Valero-Ramon Z, Michielin O, Lapinskas T, Montvila A, Martin N, Tavazzi E, Castellano M. *What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper. **Int J Environ Res Public Health.*** 2020 Sep 11;17(18):6616. (IF: **2.84**).
 22. Achard V, Aebbersold DM, Allal AS, Andratschke N, Baumert BG, Beer KT, Betz M, Breuneval T, Bodis S, De Bari B, Förster R, Franzetti-Pellanda A, Guckenberger M, Herrmann E, Huck C, Khanfir K, Matzinger O, Peguret N, Pesce G, Putora PM, Reuter C, Richetti A, Vees H, Vrieling C, Zaugg K, Zimmermann F, Zwahlen DR, Tsoutsou P, Zilli T. *A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. **Radiother Oncol.*** 2020 Sep;150:1-3. (IF: **6.28**).
 23. Franco P, Kochbati L, Siano M, De Bari B. *Suggestions for Radiation Oncologists during the COVID-19 Pandemic. **Biomed Res Int.*** 2020 May 26;2020:4892382. (IF: **3.41**)*.
 24. Doussot A, Vernerey D, Rullier E, Lefevre JH, Meillat H, Cotte E, Piessen G, Tuech JJ, Panis Y, Mege D, Meurisse A, De Bari B, Heyd B, Lakkis Z; French Research Group of Rectal Cancer Surgery (GRECCAR). *Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group. **Ann Surg Oncol.*** 2020 Oct;27(11):4286-4293. (IF: **4.17**).
 25. De Bari B, Dachele M, Palmu M, Kaylor S, Schiappacasse L, Guckenberger M; ESTRO FALCON core. *Short interactive workshops reduce variability in contouring treatment volumes for spine stereotactic body radiation therapy: Experience with the ESTRO FALCON programme and EduCase™ training tool. **Radiother Oncol,*** 2017 Nov 20. doi: 10.1016/j.radonc.2017.10.038. (IF: **4.3**)*.
 26. Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D; International Oncology Panel and European Cancer Patient Coalition collaborators. *Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. **Lancet Oncol.*** 2020 May 13. doi: 10.1016/S1470-2045(20)30278-3. (IF: **35.39**)
 27. Terlizzi M, Le Pechoux C, Salas S, Rapeaud E, Lerouge D, Sunyach MP, Vogin G, Sole CV, Zilli T, Lutsyk M, Mampuya A, Calvo FA, Attal J, Karahissarlian V, De Bari B, Ozsahin M, Baumard F, Krenqli M, Gomez-Brouchet A, Sargos P, Rochcongar G, Bazille C, Roth V, Salleron J, Thariat J. *Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network. **Int J Radiat Oncol Biol Phys.*** 2020 Apr 11:S0360-3016(20)30985-8. (IF: **6.2**)
 28. Krenqli M, Cena T, Zilli T, Jerezek-Fossa BA, De Bari B, Villa Freixa S, Kaanders JHAM, Torrente S, Pasquier D, Sole CV, Lutsyk M, Dincbas FO, Habboush Y, Fariselli L, Dragan T, Baumert BG, Khanfir K, Ugurluer G, Thariat J. *Radiotherapy in the treatment of extracranial hemangiopericytoma/solitary fibrous tumor: Study from the Rare Cancer Network. **Radiother Oncol.*** 2020 Mar;144:114-120. (IF: **5.2**)

29. Cacicedo J, Navarro-Martin A, Gonzalez-Larragan S, De Bari B, Salem A, Dahele M. *Systematic review of educational interventions to improve contouring in radiotherapy*. **Radiother Oncol**. 2020 Mar;144:86-92. (IF: **5.2**)
30. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclellan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comp rat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubm ller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jerezcek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espin s E, L gager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, M ller AC, M ller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupr t M, Rouvi re O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskim e E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. *EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees*. **Eur Urol**. 2019 Nov 16. (IF: **17.58**).
31. Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaf L, Coukos G, Harari A, Bourhis J. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. **Int J Radiat Oncol Biol Phys**. 2019 Feb 1;103(2):320-334. (IF: **6.2**).
32. Castelli J, Depeursinge A, Devillers A, Campillo-Gimenez B, Dicente Y, Prior JO, Chajon E, Jegoux F, Sire C, Acosta O, Gherga E, Sun X, De Bari B, Bourhis J, de Crevoisier R. *PET-based prognostic survival model after radiotherapy for head and neck cancer*. **Eur J Nucl Med Mol Imaging**. 2019 Mar;46(3):638-649. (IF: **7.2**).
33. Leroy T, Monnet E, Guerzider S, Jacoulet P, De Bari B, Falcoz PE, Gagnet-Brun M, Lahourcade J, Alfreijat F, Almotlak H, Adotevi O, Pernet D, Polio JC, Desmarests M, Woronoff AS, Westeel V. *Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC*. **Lung Cancer**. 2019 Nov;137:23-30. (IF: **3.98**).
34. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, R del C, Rutten H, van de Velde C, Aristei C. *The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper*. **Radiother Oncol**. 2019 Aug 17. (IF: **5.25**).
35. De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Ozsahin M. *Neoadjuvant Chemoradiotherapy Delivered with Helical Tomotherapy with Daily Image Guidance for Rectal Cancer patients: Efficacy and Safety in a Large, Multi-Institutional series*. **J Cancer Res Clin Oncol**. 2019 Apr;145(4):1075-1084. (IF: **3.08**)*.
36. Salas S, Resseguier N, Blay JY, Le Cesne A, Italiano A, Chevreau C, Rosset P, Isambert N, Soulie P, Cupissol D, Delcambre C, Bay JO, Dubray-Longeras P, Krengli M, De Bari B, Villa S, Kaanders JHAM, Torrente S, Pasquier D, Thariat JO, Myroslav L, Sole CV, Dincbas HF, Habboush JY, Zilli T, Dragan T, Khan R K, Ugurluer G, Cena T, Duffaud F, Penel N, Bertucci F, Ranchere-Vince D, Terrier P, Bonvalot S, Macagno N, Lemoine C, Lae M, Coindre JM, Bouvier C. *Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database*. **Ann Oncol**. 2017 Aug 1;28(8):1979-1987. (IF: **11.8**).
37. Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters BR, Van Vulpen M, Khoo V, Henry A, Bossi A, De Meerleer G, Fonteyne V. *ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer*. **Radiother Oncol**. 2018 Apr;127(1):49-61. (IF: **4.3**).

38. De Bari B, Lestrade L, Franzetti-Pellanda A, Jumeau R, Biggiogero M, Kountouri M, Matzinger O, Miralbell R, Bourhis J, Ozsahin M, Zilli T. *Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.* **J Cancer Res Clin Oncol.** 2018 Apr;144(4):781-789 (IF: **3.08**)*.
39. Castelli J, Depeursinge A, De Bari B, Devillers A, de Crevoisier R, Bourhis J, Prior JO. *Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?* **Clin Nucl Med.** 2017 Jun;42(6):e281-e285. (IF: **6.2**).
40. Franzetti Pellanda A, De Bari B, Deniaud Alexandre E, Krengli M, Van Houtte P, Richetti A, Villà S, Goldberg H, Szutowicz-Zielinka E, Bolla M, Hoogenraad WJ, Vaneijkereen M, Poortmans P, Collon T, Yavuz A, Chan S., Landmann C, Kirkove Houssiau C, Scandolaro L, Bernier J, Mirimanoff RO, Ozsahin M. *Primary Uterine Leiomyosarcoma: outcome and prognostic factors in 110 consecutive patients – a Rare Cancer Network study.* **Chin J Cancer Res.** 2017. 29(6): 1-12 (IF: **3.0**) *.
41. De Bari B, Stish B, Ball MW, Habboush Y, Sargos P, Krengli M, Bossi A, Stabile A, Sole Pesutic C, Lestrade L, Smeenk RJ, Jereczek-Fossa BA, Zilli T, Créhange G, Alongi F, Zaorsky N, Ozsahin M. *Prostatic sarcoma: a contemporary multicenter Rare Cancer Network study.* **Prostate**, 2017 Jul;77(10):1160-1166. (IF: **3.7**)*.
42. Castelli J, Depeursinge A, Ndoh V, Prior JO, Ozsahin M, Devillers A, Bouchaab H, Chajon E, de Crevoisier R, Scher N, Jegoux F, Laguerre B, De Bari B, Bourhis J. *A PET-based nomogram for oropharyngeal cancers.* **Eur J Cancer.** 2017 Feb 23;75:222-230. (IF: **6.1**)
43. Lestrade L, Zilli T, Kountouri M, Jumeau R, Matzinger O, Bourhis J, Miralbell R, Ozsahin M, De Bari B. *Early-stage Favourable Anal Cancer: A Retrospective Analysis of Clinical Outcomes of a Moderately Low Dose Elective Nodal Intensity-modulated Radiotherapy Schedule.* **Clin Oncol (R Coll Radiol).** 2017 Jul;29(7):e105-e109. (IF: **3.2**).
44. Castelli J, Depeursinge A, De Bari B, Devillers, A, de Crevoisier R, Bourhis J, Prior JO. *Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer treated with definitive radiotherapy: Which threshold is the best predictor of local control?* **Clin Nucl Med**, 2017 Jun;42(6):e281-e285. (IF: **4.2**).
45. De Bari B, Jumeau R, Bouchaab H, Vallet V, Matzinger O, Troussier I, Mirimanoff RO, Wagner D, Hanhloser D, Bourhis J, Ozsahin M. *Efficacy and Safety of Helical Tomotherapy with Daily Image Guidance in Anal Canal Cancer Patients.* **Acta Oncol.** 2016 Jun;55(6):767-73. (IF: **3.16**) *.
46. Eriksen JG, Salembier C, Rivera S, De Bari B, Berger D, Mantello G, Müller AC, Martin AN, Pasini D, Tanderup K, Palmu M, Verfaillie C, Pötter R, Valentini V; ESTRO. *Four years with FALCON - An ESTRO educational project: Achievements and perspectives.* **Radiother Oncol.** 2014 Jul;112(1):145-9. (IF: **4.52**).
- 47. Other original articles (2003 – 2019)**
48. Franco P, De Bari B, Arcadipane F, Lepinoy A, Ceccarelli M, Furfaro G, Mistrangelo M, Cassoni P, Valgiusti M, Passardi A, Casadei Gardini A, Trino E, Martini S, Iorio GC, Evangelista A, Ricardi U, Créhange G. *Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study.* **Radiat Oncol.** 2018 Sep 10;13(1):172. (IF: **2.89**)*.
49. Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloï D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P. *Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier).* **Cancer Manag Res.** 2019 Apr 26;11:3631-3642. (IF: **2.24**).

50. De Bari B, Mazzola R, Aiello D, Aloï D, Gatta R, Corradini S, Salgarello M, Alongi F. (68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. **Cancer Radiother.** 2019 Jun;23(3):194-200. (IF: 1.26)*.
51. De Bari B, Breuneval T, Zeverino M, Godin S, Deantonio L, Geldhof C, Bourhis J, Schaefer N, Moeckli R, Prior J, Ozsahin M. Hepatobiliary scintigraphy allows the evaluation of short-term functional toxicity of liver stereotactic body radiotherapy: Results of a pilot study. **PLoS One.** 2018 Oct 10;13(10):e0204013. (IF: 2.77)*.
52. De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. **Radiol Med.** 2018 Sep;123(9):719-725. (IF: 1.4)*.
53. Lancellotta V, Iacco M, Perrucci E, Falcinelli L, Zucchetti C, De Bari B, Saldi S, Aristei C. Comparing four radiotherapy techniques for treating the chest wall plus levels III-IV draining nodes after breast reconstruction. **Br J Radiol.** 2018 Jun;91(1086):20160874. (IF: 1.9).
54. Moeckli R, Conrad M, Bolard G, Nowak M, De Bari B, Jeanneret-Sozzi W, Bourhis J, Germond JF, Bochud F. Determination of the effective dose delivered by Image Guided Radiotherapy in Head & Neck and Breast treatments. *Soumis Zeitschrift fur Medizinische Physik (Journal of Medical Physics)*, 2018 Dec;28(4):276-285. (IF: 1.5).
55. Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebbersold DM, Ozsahin M. Outcome of proximal esophageal cancer after definitive combined chemoradiation: a Swiss multicenter retrospective study. **Radiat Oncol.** 2017 Jun 14;12(1):97. (IF: 2.86).
56. De Bari B, Vallati M, Gatta R, Lestrade L, Manfrida S, Carrie C, Valentini V. Development and validation of a machine learning-based predictive model to improve the prediction of inguinal status of anal cancer patients: a preliminary report. **Oncotarget.** 2016 Jul 21. (IF: 5.0).
57. Jumeau R, Peguret N, De Bari B, Moeckli R, Soares-Rodrigues JL, Durham AD, Hojnowski S, Bourhis J, Ozsahin M, Beigelman-Aubry C. Sparing healthy lung by focusing the radiation beam flow onto the emphysematous regions in the treatment of lung cancer. **J Med Imaging Radiat Oncol.** 2016 Sep 21. (IF: 1.1).
58. De Bari B, Jumeau R, Deantonio L, Adib S, Godin S, Zeverino M, Moeckli R, Bourhis J, Prior JO, Ozsahin M. Role of functional imaging in treatment plan optimization of stereotactic body radiation therapy for liver cancer. **Tumori.** 2016 Oct 13;102(5):e21-e24. (IF: 1.1).
59. De Bari B, Franco P, Niyazi M, Cornetto AP, Qvortrup C, Martin AN, Cacicedo J, Fernandez G, Louro LV, Lestrade L, Ciammella P, Greto D, Checkrine T, Youssef E, Filippi AR, Poulsen LØ, Alongi F; AIRO Giovani (Italian Association of Radiation Oncology-Young Members Working Group), of yDEGRO (Young German Society of Radiation Oncology), of SYROG (Spanish Young Radiation Oncology Group), of SEOR (Spanish Society of Radiation Oncology), of SPRO (Portuguese Society of Radiotherapy and Oncology-Young Members Working Group), SPRO Jovem), and of FYO (The Danish Association of Young Oncologists). *The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project: How the Use of Tools in Medical Decision Making is Changing?* **Technol Cancer Res Treat.** 2016 Apr;15(2):365-76. (IF: 1.88).
60. Buglione M, Ghirardelli P, Triggiani L, Pedretti S, Pasinetti N, De Bari B, Tonoli S, Borghetti P, Spiazzi L, Magrini SM. Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. **Rep Pract Oncol Radiother.** 2015 Jul-Aug;20(4):284-91. (pas d'IF).
61. De Bari B, Vallati M, Gatta R, Simeone C, Girelli G, Ricardi U, Meattini I, Gabriele P, Bellavita R, Krengli M, Cafaro I, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Pasinetti N, Buglione M, Magrini SM. Could Machine Learning Improve the Prediction of Pelvic Nodal Status of Prostate Cancer Patients? Preliminary Results of a Pilot Study. **Cancer Invest.** 2015 Jul;33(6):232-40. (IF: 2.06).

62. De Bari B, Lestrade L, Pommier P, Maddalo M, Buglione M, Magrini SM, Carrie C. *Could concomitant radio-chemotherapy improve the outcomes of early-stage node negative anal canal cancer patients? A retrospective analysis of 122 patients.* **Cancer Invest.** 2015 Apr;33(4):114-20. (IF: 2.06).
63. De Bari B, Franco P, Ciammella P, Peruzzo Cornetto A, Greto D, Fundoni C, Filippi AR, Alongi F; AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group. *The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists.* **Tumori.** 2014 Nov-Dec;100(6):e236-42. (IF: 1.09)
64. Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Ardiet JM, Carrie C. *Role of brachytherapy in the treatment of cancers of the anal canal: Long-term follow-up and multivariate analysis of a large monocentric retrospective series.* **Strahlenther Onkol.** 2014 Jun;190(6):546-54. (IF: 4.16).
65. Franco P, De Bari B, Ciammella P, Fiorentino A, Chiesa S, Amelio D, Pinzi V, Bonomo P, Vagge S, Fiore M, Comito T, Cecconi A, Mortellaro G, Bruni A, Trovò M, Filippi AR, Greto D, Alongi F; AIRO Giovani Italian Association of Radiation Oncology, Young Members Working Group. *The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO-Young Members Working Group (AIRO Giovani).* **Tumori.** 2014 Nov-Dec;100(6):e214-9. (IF: 1.09)
66. De Bari B, Buglione M, Maddalo M, Lestrade L, Spiazzi L, Vitali P, Barbera F, Magrini SM. *External Beam Radiotherapy ± Chemotherapy in the Treatment of Anal Canal Cancer: A Single-Institute Long-Term Experience on 100 Patients.* **Cancer Invest.** 2014 Jul;32(6):248-55. (IF: 2.23).
67. Pegurri L, Buglione M, Girelli G, Guarnieri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini SM. *Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.* **Tumori.** 2014 Jan-Feb;100(1):31-7. (IF: 1.09)
68. Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Triggiani L, Magrini SM. *Role of external beam radiotherapy in the treatment of relapsing meningioma.* **Med Oncol.** 2014 Mar;31(3):866. (IF: 2.14).
69. Franco P, Ciammella P, Peruzzo Cornetto A, De Bari B, Buglione M, Livi L, Alongi F, Filippi AR. *The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists.* **Med Oncol.** 2013 Dec;30(4):729. (IF: 2.14).
70. Ciammella P, De Bari B, Fiorentino A, Franco P, Cavuto S, Alongi F, Livi L, Filippi AR; AIRO Giovani (Italian Association of Radiation Oncology-Young Members Working Group). *The "BUONGIORNO" project: burnout syndrome among young Italian radiation oncologists.* **Cancer Invest.** 2013 Oct;31(8):522-8. (IF: 2.23).
71. Udrescu C, De Bari B, Rouvière O, Ruffion A, Michel-Amadry G, Jalade P, Devonec M, Colombel M, Chapet O. *Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images.* **Cancer Radiother.** 2013 Jun;17(3):215-20. (IF: 1.48).
72. Vallati M, Gatta R, De Bari B, Magrini SM. *Clinical similarities: an innovative approach for supporting medical decisions.* **Stud Health Technol Inform.** 2013;192:1114. Impact Factor (Pas d'IF)
73. De Bari B, Alongi F, Franco P, Ciammella P, Chekrine T, Livi L, Jerezek-Fossa BA, Filippi AR. *The "PROCAINA (PROstate CANcer INDication Attitudes) Project" (Part II) – A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.* **Radiol Med.** 2013 Oct;118(7):1220-39. (IF: 1.44).
74. Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jerezek-Fossa BA, Filippi AR. *The "PROCAINA (PROstate CANcer INDication Attitudes) Project" (Part I) – A survey among Italian*

radiation oncologists on post-operative radiotherapy in prostate cancer. **Radiol Med.** 2013 Jun;118(4):660-78. (IF: 1.44).

75. Lestrade L, De Bari B, Montbarbon, Pommier P, Carrie C. *Radiochemotherapy and brachytherapy could be the standard treatment of anal canal cancer in elderly patients? A retrospective single centre analysis.* **Med Oncol.** 2013 Mar; 30(1): 402. (IF: 2.14).
76. Elkholti Y, Cosmidis A, Ardiet JM, Laffay L, De Bari B. *Adenoid cystic carcinoma of the nasopharynx: a case report and a discussion about prognostic factors and the role of local treatments.* **Tumori.** 2013 Mar-Apr;99(2):e55-60. (IF: 1.01).
77. Laffay L, Depaep L, d'Hombres A, Balme B, Thomas L, De Bari B. *Histological features and treatment approach of trichoblastic carcinomas: from a case report to a review of the literature.* **Tumori.** 2012 Mar-Apr; 98(2): 46e-49e. Review. (IF: 1.01).
78. Balducci M, Fiorentino A, De Bonis P, Chiesa S, Manfrida S, D'Agostino GR, Mantini G, Frascino V, Mattiucci GC, De Bari B, Mangiola A, Micciché F, Gambacorta MA, Colicchio G, Morganti AG, Anile C, Valentini V. *Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.* **Med Oncol.** 2012 Jun 7. (IF: 2.14).
79. De Bari B, Lestrade L, Souquet PJ, Pacheco Y, Geriniere L, Guibert B, Mornex F. *Single French centre retrospective analysis of local control after high dose radiotherapy with or without chemotherapy and local control for Pancoast tumours.* **Cancer Radiother.** 2012 Apr; 16(2): 107-14 (French). (IF: 1.48).
80. Udrescu C, Jalade P, De Bari B, Michel-Amadry G, Chapet O. *Evaluation of the respiratory prostate motion with four-dimensional computed tomography scan acquisitions using three implanted markers.* **Radiother Oncol.** 2012 May; 103(2): 266-9. (IF: 5.58).
81. De Bari B, Ait Erraisse M, Chekrine T, Rabilloud M, Shakir Shakir I, Lebras L, Favrel V. *Does weight loss predict accuracy of setup in head and neck cancer patients treated with Intensity-Modulated Radiation Therapy?* **Radiol Med** 2012; 117 (5): 885-891. (IF : 1.44).
82. Balducci M, Chiesa S, Chieffo D, Manfrida S, Dinapoli N, Fiorentino A, Micciché F, Frascino V, Anile C, Valentini V, De Bari B. *The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.* **J Neurooncol** 2012; 106: 315-323. Erratum in J Neurooncol 2012; 106: 325. (IF: 2.9).
83. Balducci M, Chiesa S, Diletto B, D'Agostino GR, Mangiola A, Manfrida S, Mantini G, Albanese A, Fiorentino A, Frascino V, De Bari B, Micciché F, De Rose F, Morganti AG, Anile C, Valentini V. *Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.* **Neuro Oncol.** 2012 Jan; 14(1): 79-86. (IF: 5.48).
84. De Bari B, Lestrade L, Chekrine T, Shakir Shakir I, Ardiet JM, Chapet O, Mornex F. *Should the Treatment of Anal Carcinoma be Adapted in the Elderly? A Retrospective Analysis of Acute Toxicities in a French Centre and a review of the literature.* **Cancer Radiother.** 2012 Feb;16(1):52-7 (French). (IF: 1.48).
85. Balducci M, Di Rito A, Mantini G, Manfrida S, Chiesa S, Frascino V, D'Agostino GR, Valentini V, De Bari B. *Role of radiotherapy in the treatment of fibrosarcoma of the spermatic cord: a case report and review of the literature.* **Tumori.** 2011 Nov-Dec; 97(6): 36e-8e. (IF: 1.01).
86. De Bari B, Chiesa S, Filippi AR, Gambacorta MA, D'Emilio V, Murino P, Livi L; AIRO (Italian Association of Radiation Oncology) and the AIRO Palliative Care Group. *The "INTER-ROMA Project" - INTERview for Radiation Oncologists on Metastasis Approach: an Italian survey.* **Tumori** 2011 Mar-Apr;97(2):177-84. (IF: 0.79).
87. Chekrine T, De Bari B, Cassier P, Kulisa M, Chapet O, Mornex F. *Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature.* **Cancer Radiother.** 2011 Jun;15(3):250-253 (French). (IF: 1.43).

88. Balducci M, Chiesa S, Manfrida S, Rossi E, Za T, Frascino V, De Bari B, Hohaus S, Cellini F, Mantini G, D'Agostino GR, Gambacorta MA, Leone A, Valentini V, De Stefano V. *Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms: Long-Term Experience*. **Strahlenther Onkol**. 2011 Feb; 187(2): 114-119. Epub 2011 Jan 24. (IF: 3.7).
89. De Bari B, Sellal N, Mornex F. *4D-CT scan and radiotherapy for hepatocellular carcinoma: Role in the definition of internal target volume (ITV)*. **Cancer Radiother** 2011; 15: 43–48 (French). (IF: 1.43).
90. Balducci M, De Bari B, Manfrida S, D'Agostino GR, Valentini V. *Treatment of Merkel's Cell Carcinoma with Radiotherapy and Imiquimod (AldaraTM): a case report*. **Tumori** 2010; 96: 508-511. (IF: 1.0).
91. Balducci M, D'Agostino GR, Manfrida S, De Renzi F, Colicchio G, Apicella G, Mangiola A, Fiorentino A, Frascino V, Mantini G, De Bari B, Pompucci A, Valentini V, Anile C, Cellini N. *Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study*. **J Neurooncol**. 2010 Mar;97(1):95-100. (IF: 2.32).
92. Sgambato, A. Camerini, G. Pani, R. Cangiano, B. Faraglia, G. Bianchino, B. De Bari, T. Galeotti, A. Cittadini. *Increased expression of Cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts*. **British Journal of Cancer** Vol. 88, 1956-1962, 2003. (IF: 4.63).

Reviews of the literature

- 1) Castelli J, Simon A, Lafond C, Perichon N, Rigaud B, Chajon E, De Bari B, Ozsahin M, Bourhis J, de Crevoisier R. *Adaptive radiotherapy for head and neck cancer*. **Acta Oncol**. 2018 Oct;57(10):1284-1292. (IF: **3.2**).
- 2) Alongi F, Arcangeli S, De Bari B, Giaj-Levra N, Fiorentino A, Mazzola R, Trovò M. *Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature*. **Crit Rev Oncol Hematol**. 2017 Apr;112:67-71. (IF: **4.49**).
- 3) Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, Prior J, Ozsahin M, de Crevoisier R, Bourhis J. *Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy*. **Crit Rev Oncol Hematol**. 2016 Dec;108:40-51. (IF: **5.0**)*.
- 4) Cacicedo J, Navarro A, Del Hoyo O, Gomez-Iturriaga A, Alongi F, Medina JA, Elicin O, Skanjeti A, Giammarile F, Bilbao P, Casquero F, De Bari B, Dal Pra A. *Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist*. **Br J Radiol**. 2016 Nov;89(1067):20160217. (IF: **1.8**).
- 5) De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jerezek-Fossa BA; on the behalf of the Italian Association of Radiation Oncology (AIRO). *Extreme hypofractionation for early prostate cancer: Biology meets technology*. **Cancer Treat Rev**. 2016 Nov;50:48-60. (IF: **7.9**)*.
- 6) Allemann P, Mantziari S, Wagner D, Digkha A, Ozsahin E, De Bari B, Dorta G, Godat S, Montserrat F, Sempoux C, Brunel C, Demartines N, Schäfer M. *Curative treatment for esophageal cancer: results of a multidisciplinary consensus*. **Rev Med Suisse**. 2016 Jun 15;12(523):1165-9. (pas d'IF).
- 7) Jerezek-Fossa BA, Ciardo D, Petralia G, Bellomi M, De Bari B, De Cobelli O, Orecchia R. *Primary focal prostate radiotherapy: Do all patients really need whole-prostate irradiation?* **Crit Rev Oncol Hematol**. 2016 Sep;105:100-11. (IF: **5.0**)*.
- 8) De Bari B, Porta L, Mazzola R, Alongi F, Wagner AD, Schäfer M, Bourhis J, Ozsahin M. *Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy*. **Crit Rev Oncol Hematol**. 2016 Jul;103:49-61. (IF: **5.0**)*.
- 9) De Bari B, Deantonio L, Bourhis J, Prior JO, Ozsahin M. *Should we include SPECT lung perfusion in radiotherapy treatment plans of thoracic targets? Evidences from the literature*. **Crit Rev Oncol Hematol**. 2016 Jun;102:111-7. (IF: **5.0**)*.

- 10) De Bari B, Alongi F, Mortellaro G, Mazzola R, Schiappacasse L, Guckenberger M. *Spinal Metastases: Is Stereotactic Body Radiation Therapy supported by evidences?* **Crit Rev Oncol Hematol**. 2016 Feb;98:147-58. (IF: **4.0**)*.
- 11) Arcangeli S, Ramella S, De Bari B, Franco P, Alongi F, D'Angelillo RM. *A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective*. **Crit Rev Oncol Hematol**. 2016 Jan;97:322-7. (IF: **4.0**)*.
- 12) Arcangeli S, Zilli T, De Bari B, Alongi F. *"Hit the primary": A paradigm shift in the treatment of metastatic prostate cancer?* **Crit Rev Oncol Hematol**. 2016 Jan;97:231-7. (IF: **4.0**)*.
- 13) Alongi F, Fiorentino A, De Bari B. *SBRT and extreme hypofractionation: A new era in prostate cancer treatments?* **Rep Pract Oncol Radiother**. 2015 Nov-Dec;20(6):411-6. (pas d'IF)
- 14) Stebler V, Pauchard B, Schmidt S, Valerio M, De Bari B, Berthold D. *Testicular cancer: a model to optimize the radiological follow-up*. **Rev Med Suisse**. 2015 May 20;11(475):1144-8. French (pas d'IF).
- 15) De Bari B, Filippi AR, Mazzola R, Bonomo P, Trovò M, Livi L, Alongi F. *Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies*. **Cancer Treat Rev**. 2015 Jun;41(6):511-8. (IF: **6.4**)*.
- 16) De Bari B, Daidone A, Alongi F. *Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature*. **Crit Rev Oncol Hematol**. 2015 Jun;94(3):360-370. (IF: **4.0**)*.
- 17) D'Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F. *Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era*. **Crit Rev Oncol Hematol**. 2015 Feb;93(2):136-48. (IF: **4.0**)*.
- 18) De Bari B, Alongi F, Lestrade L, Giammarile F. *Choline-PET in prostate cancer management: The point of view of the radiation oncologist*. **Crit Rev Oncol Hematol**. 2014 Sep;91(3):234-247. (IF: **4.5**)*
- 19) De Bari B, Fiorentino A, Arcangeli S, Franco P, D'Angelillo RM, Alongi F. *From radiobiology to technology: what is changing in radiotherapy for prostate cancer*. **Expert Rev Anticancer Ther**. 2014 May;14(5):553-64. (IF: 2.06).
- 20) De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, D'Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco P, R Filippi A, Alongi F. *Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting*. **Tumori**. 2013 Nov-Dec;99(6):637-49. (IF: 1.09).
- 21) De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jerezek-Fossa BA. *Salvage therapy of small volume prostate cancer nodal failures: A review of the literature*. **Crit Rev Oncol Hematol**. 2014 Apr;90(1):24-35. (IF: **4.5**)*.
- 22) Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM, Scorsetti M, Orecchia R, Jerezek-Fossa BA. *Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review*. **Crit Rev Oncol Hematol**. 2013 Dec;88(3):550-63. (IF: **4.5**)*.
- 23) De Bari B, Bosset JF, Gérard JP, Maingon P, Valentini V. *Evidences in multidisciplinary management of rectal cancer*. **Cancer Radiother**. 2012 Dec;16(8):711-20. (IF: 1.48).
- 24) De Bari B, Guillet M, Mornex F. *Stereotactic body radiation therapy (SBRT) in the treatment of liver metastases: state of the art*. **Cancer Radiother**. 2011;15:72-76 (French). (IF: **1.43**)*.
- 25) De Bari B, Pointreau Y, Rio E, Mirabel X, Mornex F. *Normal tissue tolerance to external beam radiation therapy: liver*. **Cancer Radiother**. 2010; 14: 344-349 (French). (IF: **1.43**)*.

Lettres aux éditeurs/Editorials

- 1) Alongi F, de Crevoisier R, Corradini S, Créhange G, De Bari B. *Daily IGRT for prostate cancer: Can we stop the train?* **Radiother Oncol**. 2018 Aug;128(2):389-390. (IF: **5.0**)*.
- 2) De Bari B, Durham A, Bourhis J, Ozsahin M. *Can Segmentectomy Still Be Proposed As an Alternative to Lobectomy in 2016?* **J Clin Oncol**. 2016 Nov 28;JCO2016699140. (IF: **20.9**)*.
- 3) De Bari B, Ozsahin M, Bize P, Boussaha T, Deplanque G, Wagner D, Bourhis J, Denys A. *Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma?* **J Clin Oncol**. 2016 Aug 10;34(23):2798-9. (IF: **20.9**)*.
- 4) De Bari B, Zietman AL, Poortmans P. *Prostatectomy vs radiation therapy for prostate cancer: The (still) unsolved dilemma*. **Radiother Oncol**. 2016 May;119(2):368. (IF: **4.8**)*.
- 5) De Bari B, Arcangeli S, Alongi F. *Re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy*. **Eur urol** 2014;65:546-51. *Eur Urol*. 2015 Feb;67(2):e26. (IF: **13.9**)*.
- 6) De Bari B, Alongi F, Arcangeli S. *Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after post-prostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patient*. **Eur urol** 2014;66:1024-30. *Eur Urol*. 2014 Dec;66(6):e111-2. (IF: **13.9**)*.
- 7) Arcangeli S, De Bari B, Alongi F. *Toxicity of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: A Potential Comparison Bias*. **J Clin Oncol**. 2014 Sep 2. (IF: **18.04**)*.
- 8) Alongi F, De Bari B, Scorsetti M. *Could single-high-dose radiotherapy be considered the new frontier of stereotactic ablative radiation therapy?* **Tumori**. 2014 May-Jun;100(3):92e-93e. (IF: 1.09).
- 9) De Bari B, Arcangeli S, Alongi F. *In reply to Gandaglia et al*. **Ann Oncol**. 2014 Jun 8. pii: mdu213. (IF: **7.3**)*.
- 10) De Bari B, Chekrine T, Shakir Shakir I, Ardiet JM, Gerard JP, Chapet O, Mornex F, *Should the Treatment of Anal Carcinoma be Adapted in the Elderly? A Retrospective Analysis of Toxicities in a French Centre*. **J Clin Gastroenterol**. 2011 Sep;45(8):738-9. (IF: **2.2**)*.
- 11) De Bari B, Fiorentino A, Alongi F. *Reply to Sooriakumaran et al. - Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes*. **Br Med Journal** 2014; 348: g1502. (IF: **17.2**)*.
- 12) Filippi AR, Alongi F, Ciammella P, De Bari B, Franco P, Livi L. *A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group)*. **Rep Pract Oncol Radioth**. 2012; 17(5): 259-261. (pas d'IF).

Article in journals indexed in Index Medicus :

- A. Gatta R, Vallati M, Cappelli C, De Bari B, Salvetti M, Finardi S, Muiesan M, Valentini V, Castellano M. (2016). *Bridging the Gap Between Knowledge Representation and Electronic Health Records*. In: Proceedings of the 9th International Conference on Health Informatics. SCITEpress.
- B. Gatta R, Vallati M, De Bari B, Pasinetti N, Cappelli C, Pirola I, Salvetti M, Buglione M, Muiesan M, Magrini S, Castellano M. (2014). *Information Retrieval in Medicine: an Extensive Experimental Study*. In: Proceedings of the 7th International Conference on Health Informatic. Angers, France: SciTePress.
- C. Vallati M, De Bari B, Gatta R, Ozsahin M. *The Impact of Different Training Sets on Medical Documents classification*. Proceedings of the 3rd International Workshop on Artificial Intelligence and Assistive Medicine (AI-AM/NetMed 2014). Available at <http://ceur-ws.org> (ISSN 1613-0073)
- D. Vallati M, De Bari B, Gatta R, Buglione M, Magrini S, Jereczek-Fossa B, Bertoni F. (2013) *Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients*. In: Artificial Intelligence Applications

and Innovations 9th IFIP WG 12.5 International Conference, AIAI 2013, Paphos, Cyprus, September 30 – October 2, 2013, Proceedings. Paphos, Cyprus: Springer. pp. 61-70. ISBN 978-3-642-41141-0.

E. Vallati M, Gatta R, De Bari B, Magrini SM. *Clinical Similarities: an innovative approach for supporting Medical Decisions*. In Proceedings of the 14th World Congress on Medical and Health Informatics (MedInfo-13, Copenhagen, Denmark on 20-23 August, 2013).

F. Mattiucci GC, D'Agostino GR, De Bari B, Mangiacotti MG, Smaniotto D, Trodella L. *Biological optimization of the dose in pancreatic cancer*. Rays. 2004 Jul-Sep;29(3):301-8.

G. Chapet O, De Bari B. *La radiothérapie hypofractionnée des cancers de prostate*. Reflexions en médecine oncologique Vol. 36, n° 7 Jan. 2010. (ISSN: 1767-655X). Article in French.

H. Chapet O, De Bari B, Azria D. *Prostate radiotherapy: evolution of concepts*. La lettre du cancerologue 15; 10: 530-536. (ISSN: 1165-113X, journal indexed in the base PASCAL). Article in French.

I. Sellal N; Mornex F; De Bari B *Adaptation du traitement du cancer du canal anal chez les patients âgés: quelles évidences dans la littérature? (Treatment of cancer of the anal canal in the elderly: review of the literature)* Le journal d'Onco-gériatrie 2011;2(2):64-69. (ISSN: 2106-8534, journal indexed in the base INIST-CNRS, Cote INIST: 28063, 35400019045898.0010).

Books chapters:

- De Bari B, Alongi F, Jerecz-fossa BA. Book title: Controversies in Prostate Cancer III. Title of the chapter: Oligometastatic disease. Emiral Ediciones. 2018, In press. ISBN: 978-84-617-7784-6.

- Matter M, Digkila A, Gay B, De Bari B, Diezi M, Raymond E. Book title: Induction Chemotherapy – Integrated treatments programs for locally advanced cancers. Title of the chapter: Induction treatment in sarcomas. Ed. By Aigner KR, Stephens FO. 2nd Edition. Springer Edition. 2016. ISBN 978-3-319-28773-7.

- Eurocancer 2011 - “Cancers de la tête et cou: le traitement des récurrences” (“Head and Neck cancers : the treatment of local relapses”) Eds. Boiron M, Marty M. John Libbey Eurotext (ISBN 978-2-7420-0805-6) pp 329-330.

Abstracts and Posters (National and International Meetings)

Since 2005, co-authors of more than 180 abstracts in National or International Congresses (AIRO, SFRO, SASRO, ESTRO, ASTRO, IMACC)

Invitation to National or International Meetings :

As chairman :

- 2009: Young AIRO annual national congress.
- 2009: Young AIRO session during annual A.I.R.O. national congress.
- 2010: Young AIRO annual national congress.
- 2010: Young AIRO session during annual A.I.R.O. national congress.
- 2011: Young AIRO annual national congress.
- 2012: ESTRO31 meeting - Proffered papers session Clinical 1: Stereotactic RT.
- 2014: Young AIRO annual national congress.
- 2018: EMUC18
- 2019: EMUC19

As speaker:

- 2008: Oral communication to the International Congress on “New diagnostic and therapeutic approaches and future perspectives in Neuro-Oncology” (Napoli, April 14th - 16th) with the abstract “Prognostic meaning of p53, c-erb-B2, beta and gamma catenine, mib1 and G-FAP expression in a long term survival population of adult medulloblastoma”.

- 2009: Invited speaker to the “2^{ème} Pneumo Academie Rhône Alpine (Aix Les Bains, 24th-25th Avril)” with the presentation “Cancer Bronchique: d’un syndrome paranéoplasique à la radiothérapie stereotaxique”.
- 2009: 3rd edition of F.O.R.C.E. 1 (1ere Formation des Oncologues à la Recherche Clinique d’Excellence) where he presented the PHESTER (Prostate Hypofractionated Extracranial Stereotactic ExacTract Radiotherapy) study, a phase II study to evaluate the technical and clinical feasibility of exclusive stereotactic radiation therapy (36 Gy in six fractions) for low-risk prostate cancer.
- 2009: Invited speaker during the 19th edition of SFRO National Congres (Paris, October 20th-22th) « Radiothérapie et chimio-embolisation intra-artérielle de l’hépatocarcinome inopérable et non traitable par radiofréquence : résultats d’une étude de phase II».
- 2010: Oral communication at the 9th Biennale Monégasque de Cancérologie (Monaco, January) « Efficacité de la radiothérapie conformationnelle (CRT) combiné à la chimio-embolisation trans-artérielle (TACE) pour les nodules solitaires d’hépatocarcinome inopérables qui ne peuvent bénéficier de ablation par radiofréquence: une étude de phase II » (session: future of radiotherapy).
- 2011 : Invited speaker to the 3th edition of Monaco Age Oncology (Monaco, February) “Treatment of anal cancer” (session: Clinical Trials: results and perspectives).
- 2011: invited speaker to the 3th edition of Pneumo Academie Rhone Alpes (Lyon, March) “Role of the IGRT in 2011 in the treatment of non-small cell lung cancer”.
- 2011: invited speaker during the Young session of the SEOR (Spanish Society of Radiation Oncology) national congress (Madrid, June) with the presentation “Experiencia y Programa Científico de la Sociedad Joven Italiana” (Experience and Scientific Program of Young AIRO).
- 2011: invited speaker during the “EuroCancer” (Paris, June 21st-23th) with the presentation “Treatment of local relapses in Head and Neck cancers” (session: Radiotherapy).
- 2011: Invited speaker during the Young AIRO meeting (Rome, June 25th) with a presentation about the ESTRO FALCON Project.
- 2011: Invited speaker during the ESTRO31 meeting (Barcelona, Spain, 9th -13th) with a presentation about the Results of the Young Task Force survey.
- 2013: Oral communication at the Poster Discussion session of the 2nd ESTRO Forum (Geneva, Switzerland, 19th-23rd April) abstract “To predict nodal status using Artificial Intelligence approaches in prostate cancer: beyond the Roach formula?” (authors: De Bari B, Vallati M, Gatta R, Buglione M, Girelli G, Munoz F, Meattini I, Cagna E, Pegurri L, Magrini SM).
- 2013: Oral communication at the Poster Discussion during the 2nd ESTRO Forum (Geneva, Switzerland, 19th-23rd Avril) with the abstract “Brachytherapy in the treatment of anal canal cancers: a large monocentric retrospective series” (authors: Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Carrie C).
- 2013: Invited speaker during the 6th A.I.R.O. Young National Meeting (Rimini, Italy, 18th May) with the presentation “Local therapies for local and metastatic relapses in prostate cancer: only palliation?”
- 2013: Oral communication during the 9th IFIP International Conference on Artificial Intelligence Applications & Innovations (AIAI 2013) (Paphos, Cyprus, 30th September - 2nd October) with the abstract “Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients” (authors: Vallati M, De Bari B, Gatta R, Buglione M, Magrini S, Jereczek-Fossa B, Bertoni F).
- 2014: Invited speaker during the ESTRO 33 congress (Vienna, 4-8/4/2014) with a presentation about “Experience of ESTRO fellows / exchange programmes”.
- 2014: Oral communication at SASRO 2014 (Lugano, June 2014) with the abstract “Machine Learning can predict the pelvic nodal status of prostate cancer (PC) patients” (De Bari B, Vallati M, Gatta R, Girelli G, Meattini I, Ricardi U, Bertoni F, Buglione M, Krenegli M, Magrini SM).

- 2015: Oral communication at SASRO 2015 (Basel, June 2015) with the abstract “Acute toxicity in rectal cancer patients undergoing neoadjuvant treatment and tumor regression rate: an unexpected correlation?” (De Bari B, Saidi A, Hanhloser D, Wagner D, Yan P, Matzinger O, Bourhis J, Ozsahin M).
- 2015: Invited speaker at ESTRO35 (Vienna, Austria) with a speech about « Experience of ESTRO fellows / exchange programmes ».
- 2015: Invited speaker to present a clinical case of locally advanced prostate cancer in the context of a Multidisciplinary Tumor Board at the 18th ECCO - 40th ESMO European Cancer Congress (Vienna 25-29 Sept)
- 2015: Co-chair of the contouring workshop on MRI for focal therapy in prostate cancer during the EMUC 2015 (Barcelona, 12-15/09/2015).
- 2016: Oral communication at SASRO 2016 (Sursee, August 2016) with the abstract “Impact of the radiation dose on the pulmonary perfusion assessed using lung scintigraphy ». (Authors : De Bari B, Godin S, Zeverino M, Breuneval T, Prior J, Bourhis J, Moeckli R, Ozsahin M).
- 2016: Oral communication at SASRO 2016 (Sursee, August 2016) with the abstract « Impact of the radiation dose on hepatic perfusion evaluated using liver scintigraphy mebrofenin ». (Authors : De Bari B, Breuneval T, Zeverino M, Godin S, Prior J, Bourhis J, Moeckli R, Ozsahin M).
- 2017: Chair of the “Young ESTRO session” at ESTRO36 (Vienna, Autriche) during the session « Young ESTRO meets ESTRO School ».
- 2017: Oral communication at the ESTRO36 meeting (Vienna, Austria) with the abstract « Prostatic sarcomas: a large multicentric Rare Cancer Network study » (auteurs: De Bari B, Stish B, Habboush Y, Sargos P, Krengli M, Bossi A, Stabile A, Sole Pesutic C, Lestrade L, Smeenk RJ, Jerezek-Fossa B, Alongi F, Ozsahin M).
- 2018: Invited speaker: “Controversies and contradictions in staging of prostate cancer” at the EMUC18 (Amsterdam, 8-11.11.2018).
- 2018: Co-chair of the contouring workshop on “Post-operative radiotherapy in prostate cancer” at EMUC18 (Amsterdam, 8-11.11.2018).
- 2018: Invited speaker: “Burnout in young radiation oncologists” at the 60th ASTRO Annual meeting (San Antonio, USA 21-24 Oct).
- 2018: Selected poster “Clinical outcomes of rectal squamous cell carcinomas treated with chemoradiotherapy with or without surgery: a Rare Cancer Network study” at the 60th ASTRO Annual meeting (San Antonio, USA 21-24 Oct).
- 2019: Co-chair of the contouring workshop on “Pelvic nodal irradiation: Any news in the the new era of imaging?” at EMUC19 (Vienna, 14-17.11.2019).
- 2021: Poster Discussion “Could 18-FDG PET/CT radiomics features predict the locoregional progression free survival in locally advanced esophageal cancer (LA-EC)?” at the ESTRO 2021 Annual meeting (Madrid, 27-31.08.2021).
- 2021: Poster discussion “Prognostic PET/CT Biomarkers in anal cancer patients treated with chemoradiotherapy” at the 1st International Multidisciplinary Anal Cancer Conference (IMACC2021) (Aarhus, 11-12.2021).
- 2021: Poster discussion “Is it possible to optimize the prescription of PET/CT and MRI during the follow-up of anal cancer patients?” at the 1st International Multidisciplinary Anal Cancer Conference (IMACC2021) (Aarhus, 11-12.2021).
- 2021: Poster discussion “Is it possible to optimize the prescription of PET/CT and MRI during the follow-up of anal cancer patients?” at the 1st International Multidisciplinary Anal Cancer Conference (IMACC2021) (Aarhus, 11-12.2021).

La Chaux-de-Fonds, 04.09.2025

De Bari Berardino, MD, PD

A handwritten signature in black ink, appearing to read 'Bari Berardino', written in a cursive style.